Skip to main navigation Skip to search Skip to main content

Pharmacotherapy considerations in transgender individuals living with human immunodeficiency virus

  • Melissa E. Badowski
  • , Nicholas Britt
  • , Emily C. Huesgen
  • , Michelle M. Lewis
  • , Misty M. Miller
  • , Kathleen Nowak
  • , Elizabeth Sherman
  • , Renata O. Smith

Research output: Contribution to journal › Review article › peer-review

Abstract

Pharmacotherapy considerations are often a concern for transgender individuals who are living with human immunodeficiency virus (HIV) due to concerns for drug–drug interactions between their hormone and antiretroviral therapies. Many of the first-line therapies offered to patients for the management of HIV have reduced concerns for safety, resistance, and drug–drug interactions. In this review, we highlight common medications and important considerations for caring for transgender people living with HIV.
Original languageEnglish
Pages (from-to)299-314
Number of pages16
JournalPharmacotherapy
Volume41
Issue number3
DOIs
StatePublished - Jan 2021

Bibliographical note

© 2021 Pharmacotherapy Publications, Inc.

ASJC Scopus Subject Areas

  • Pharmacology (medical)

Keywords

  • antiretroviral therapy
  • hormone therapy
  • human immunodeficiency virus
  • transgender
  • Drug Interactions
  • Transgender Persons
  • Humans
  • Female
  • Male
  • HIV Infections/drug therapy

Disciplines

  • Medical Pharmacology

Fingerprint

Dive into the research topics of 'Pharmacotherapy considerations in transgender individuals living with human immunodeficiency virus'. Together they form a unique fingerprint.

Cite this